Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02004262 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting
A Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, sponsored by Aduro Biotech.
- Completed
- Registry status
- Phase 2
- Development phase
- 303
- Enrollment target
- 20
- Study locations
NCT02004262: Completed Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, sponsored by Aduro Biotech.
NCT02004262 is a Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer that has completed, run by Aduro Biotech. The registered enrollment target is 303 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher). The trial reports 20 study locations across 17 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02004262, a Phase 2 study of 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer, has completed, sponsored by Aduro Biotech.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 303 participants
- Enrollment target
- 20
- Study locations
Study Summary
Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
Primary Outcome
OS was estimated using Kaplan-Meier (KM) methods with 95% confidence intervals (CIs), with censoring at the date when 138 deaths were reached in the Primary Cohort in the FAS. Subjects without documentation of death at the time of final analysis were censored as of the date the subject was last known to be alive on/prior to the primary analysis data cut.
Conditions Studied
Interventions
- DRUG Chemotherapy
- DRUG cyclophosphamide
- BIOLOGICAL GVAX Pancreas Vaccine
- BIOLOGICAL CRS-207
Study Locations (20)
California
- University California San Diego Moores Cancer Center - La Jolla
- University of California Mt Zion Comprehensive Cancer Center - San Francisco
- University of California Los Angeles - Santa Monica
New York
- Icahn School of Medicine at Mount Sinai - New York
- Columbia University Medical Center - New York
Arizona
- Scottsdale Healthcare Research Institute - Scottsdale
Colorado
- University of Colorado Denver - Aurora
Florida
- University of Miami/Sylvester Cancer Center - Miami
Illinois
- University of Chicago Medical Center - Chicago
Maryland
- Johns Hopkins University - Baltimore
Minnesota
- Mayo Clinic Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 303 participants |
| Start Date | 2014-02-05 |
| Est. Completion | 2016-08-23 |
| Phase | Phase 2 |
What the finished NCT02004262 record still lists
NCT02004262 is an interventional study that assigns participants to a tested intervention. The registered 303 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (128% higher).
The record links to 1 condition, with 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer appearing as the primary indexed condition, and to 4 interventions - of which Chemotherapy is the first listed.
NCT02004262 names 20 study sites across 17 states, led by California, New York, Arizona.
Frequently Asked Questions
What is clinical trial NCT02004262 about?
NCT02004262 is a clinical study titled "Safety and Efficacy of Combination Listeria/GVAX Pancreas Vaccine in the Pancreatic Cancer Setting". Test the safety, immune response and efficacy of GVAX pancreas vaccine (with cyclophosphamide) and CRS-207 compared to chemotherapy or CRS-207 alone in adults with previously treated metastatic pancreatic adenocarcinoma
What is the current status of trial NCT02004262?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 303 participants. The study started on 2014-02-05. Estimated completion is 2016-08-23.
What conditions does trial NCT02004262 study?
This clinical trial studies the following conditions: 2nd-line, 3rd-line and Greater Metastatic Pancreatic Cancer.
What interventions are being tested in trial NCT02004262?
The interventions under investigation include: Chemotherapy (DRUG), cyclophosphamide (DRUG), GVAX Pancreas Vaccine (BIOLOGICAL), CRS-207 (BIOLOGICAL).
Who is sponsoring clinical trial NCT02004262?
This trial is sponsored by Aduro Biotech, which has 7 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02004262 being conducted?
This trial has 20 study locations across Arizona, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02004262's enrollment target sits among peer trials
303 167th of 2000 higher than 1,834 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05508971 · 303 participants · NA
Treatment of Obstructive Sleep Apnea With Personalized Surgery in Children With Down Syndrome (TOPS-DS)
- NCT04750616 · 304 participants · Phase 2
NAD+ Augmentation in Cardiac Surgery Associated Myocardial Injury Trial
- NCT04994717 · 304 participants · Phase 3
Study Comparing Blinatumomab Alternating With Low-intensity Chemotherapy Versus Standard of Care Chemotherapy for Older Adults With Newly Diagnosed Philadelphia-negative B-cell Precursor Acute Lymphoblastic Leukemia
- NCT06036147 · 304 participants · NA
Concussion Health Improvement Program
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI